After Oppenheimer and Canaccord Genuity gave Bluebird Bio (NASDAQ: BLUE) a Buy rating last month, the company received another Buy,
Tag: Difei Yang
Analysts Offer Insights on Healthcare Companies: Sarepta Therapeutics (NASDAQ: SRPT) and Roche Holding AG (Other OTC: RHHVF)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Sarepta Therapeutics (SRPT – Research
Avrobio (AVRO) Receives a Buy from Mizuho Securities
Mizuho Securities analyst Difei Yang maintained a Buy rating on Avrobio (AVRO – Research Report) today and set a price
Why Did Mizuho Securities Downgrade Selecta Biosciences’ Stock?
Mizuho Securities analyst Difei Yang downgraded Selecta Biosciences (SELB – Research Report) to Hold today and set a price target
Aerie Pharma (AERI) Receives a Buy from Mizuho Securities
In a report released today, Difei Yang from Mizuho Securities maintained a Buy rating on Aerie Pharma (AERI – Research
Mizuho Securities Keeps Their Buy Rating on Avrobio (AVRO)
Mizuho Securities analyst Difei Yang maintained a Buy rating on Avrobio (AVRO – Research Report) today and set a price
Mizuho Securities Thinks Akebia Therapeutics’ Stock is Going to Recover
Mizuho Securities analyst Difei Yang maintained a Buy rating on Akebia Therapeutics (AKBA – Research Report) on September 12 and